Abstract
Leflunomide is a new disease-modifying drug licensed for treatment of rheumatoid arthritis. Recently, neuropathy has been reported with leflunomide. We report a case of peripheral neuropathy in rheumatoid arthritis treated with leflunomide. Nerve conduction study and electromyogram show sensory-motor polyneuropathy of both upper and lower limbs. Leflunomide medication was discontinued and cholestryamine washout was performed with some improvement in a couple of weeks.
References
1. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999; 159:2542–50.
2. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum. 2003; 48:1513–20.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
3. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2003; 30:1182–90.
4. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000; 39:655–65.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
5. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000; 59:841–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
6. Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther. 2004; 75:580–5.
8. Hill CL. Leflunomide-induced peripheral neuropathy: rapid resolution with cholestryramine washout. Rheumatology. 2004; 43:809.
9. Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology. 2002; 41:952–3.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
10. Martin K, Bentaberry F, Dumoulin C, Miremont-Salame G, Haramburu F, Dehais J, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf. 2007; 16:74–8.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
11. Richards BL, Spies J, McGill N, Richards GW, Vaile J, Bleasel JF, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J. 2003; 62:440–3.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
12. Fox RI, Herrmann ML, Franfou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999; 93:198–208.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
13. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M, et al. Active leflunomide metabolite inhibits interleukin 1beta, tumor necrosis factor alpha, nitric oxide and metalloproteinase-3 in activated human synovial tissue cultures. Ann Rheum Dis. 2003; 62:440–3.